Avivomed, Inc., a privately held, clinical-stage, medical device company, has announced the appointment of Dan Brounstein as its new Chief Executive Officer and Board Member. Brounstein has succeeded CEO Steve Masson, who retired from his role in May and will continue to work with the company in an advisory role.

"Millions struggle with interrupted sleep, and current treatments often fall short. Dan's extensive background in neuromodulation and strong leadership skills, in developing and launching innovative medical therapies, make him the ideal leader for Avivomed and its next development," said Mudit K. Jain, PhD, Co-Founder and Chair of Avivomed's Board of Directors. 

"On behalf of the entire Board, I want to thank Steve for his dedication which led to impressive milestones reached under his tenure," added Jain.

With more than 30 years of experience, Brounstein is a successful medical device veteran with proven leadership across commercialisation, clinical execution, research and development, and reimbursement in the medical device industry. Prior to joining Avivomed, he served as Chief Strategy Officer at Saluda Medical, leading the landmark Evoke Pivotal Study and launching the Evoke® ECAP-Controlled, Closed-Loop Spinal Cord Stimulator to treat chronic pain. 

In previous roles, he held various leadership positions including Vice President of Marketing and Clinical Operations at Spinal Modulation, where he led strategy to bring DRG Stimulation to market, culminating in acquisition by St. Jude Medical (now Abbott). He holds a Bachelor of Science in Bioengineering from UC San Diego and an MBA from UC Berkeley's Haas School of Business.